$Veru Inc (VERU.US)$The possibly for a buyout by NVO is plausible and a long play. VERU drug would help with the muscle loss from Ozempic and Wegovy that NVO manufacturers.
$Veru Inc (VERU.US)$ Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
$Veru Inc (VERU.US)$ Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, f...
$Veru Inc (VERU.US)$Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
Veru Inc Stock Forum
👀
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
Veru Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.6%)
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, f...
and 102 000 share to FISCH HARRY
No comment yet